Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.


To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link


The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:

  • Type of Product
  • HPAPIs
  • Highly Potent Finished Dosage Forms


  • Company Size
  • Small-sized
  • Mid-sized
  • Large / Very Large


  • Scale of Operation
  • Preclinical / Clinical
  • Commercial


  • Type of Pharmacological Molecule
  • Small Molecules
  • Biologics


  • Type of Highly Potent Finished Dosage Form
  • Injectables
  • Oral Solids
  • Creams
  • Others


  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World


The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030report features the following companies, which we identified to be key players in this domain:

  • AbbVie Contract Manufacturing
  • Catalent
  • Evonik
  • Formosa Laboratories
  • Intas
  • Lonza
  • MabPlex
  • Pfizer CentreOne


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Landscape
  4. Company Competitive Analysis
  5. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles
  6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles
  7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles
  8. Partnerships and Collaborations
  9. Recent Expansions
  10. Capacity Analysis
  11. Market Sizing and Opportunity Analysis
  12. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates


  1. Concluding Remarks


  1. Executive Insights


  1. Appendix 1: Tabulated Data


  1. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415